The FDA's recent guidance to reduce non-human primate testing for monoclonal antibodies is a significant step towards a more efficient and human-centric approach to drug evaluation. This move aligns with the agency's 2025 roadmap to phase out animal testing, addressing long-standing concerns about the accuracy of primate studies in predicting human responses. But here's where it gets controversial: While the guidance is a positive development, it's crucial to ensure that these changes are implemented effectively. The crux of the matter lies in the continued use of animal tests, despite the availability of reliable non-animal methods. This is where Cruelty Free International's Replace Animal Tests (RAT) List comes into play, highlighting the need to address these outdated practices. The draft guidance also aligns with scientific principles emphasized by the International Council on Animal Protection in Pharmaceutical Programs (ICAPPP), such as reducing reliance on specific animal species and using more human-relevant tools. This is promising, as it encourages the adoption of modern, science-driven approaches in international regulations. Looking ahead, there's a need to modernize international requirements, particularly the routine use of a second species (typically dogs) in medicine testing. This is a critical area where we can build on the FDA's progress and push for broader updates to outdated regulatory testing requirements, ultimately accelerating the transition away from animal testing.
